Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FGEN, CAN & RMO Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

ACCESSWIRE IA May 25, 2021

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against FibroGen, Inc. - FGEN and June 11 Deadline

GlobeNewswire May 25, 2021

FIBROGEN INVESTORS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

ACCESSWIRE IA May 25, 2021

FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

GlobeNewswire May 25, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

PR Newswire May 25, 2021

SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

ACCESSWIRE IA May 25, 2021

DOX, FGEN, GOEV, PTON SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set

GlobeNewswire May 24, 2021

FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders

Newsfile May 24, 2021

FibroGen Deadline Alert

Newsfile May 24, 2021

HAGENS BERMAN Encourages FibroGen (FGEN) Investors with Losses to Contact the Firm, Deadline Approaching in Securities Fraud Class Action

Newsfile May 24, 2021

Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

ACCESSWIRE IA May 24, 2021

DEADLINE ALERT for DDD, DOX, SHRMF, and FGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire May 24, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

Newsfile May 24, 2021

Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)

GlobeNewswire May 23, 2021

FibroGen News: Berger Montague Investigates Securities Fraud Allegations Against FibroGen, Inc. (FGEN); Lead Plaintiff Deadline is June 11, 2021

Newsfile May 23, 2021

HAGENS BERMAN Reminds FibroGen (FGEN) Investors of Securities Fraud Lawsuit and June 11th Deadline, Encourages Investors with Losses to Contact the Firm

GlobeNewswire May 23, 2021

FibroGen Update

Newsfile May 23, 2021

FGEN INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

ACCESSWIRE IA May 22, 2021

FibroGen Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (FGEN); Lead Plaintiff Deadline is June 11, 2021

Newsfile May 22, 2021

FibroGen Class Action Reminder

Newsfile May 22, 2021